Tanya E. Froehlich, MD, MS, FAAP

Associate Professor, UC Department of Pediatrics

Phone 513-636-4611

Fax 513-636-4402

Email tanya.froehlich@cchmc.org

ADHD, learning disabilities.

Dr. Froehlich is a developmental-behavioral pediatrician who cares for school age children with learning and behavioral issues.  Her research has a special focus on attention-deficit/hyperactivity disorder (ADHD), and approaches the disorder from the vantage points of epidemiology, etiology, and treatment. She conducted a study reporting the national prevalence of ADHD in U.S. children based on DSM-IV criteria (published in the Archives of Pediatrics and Adolescent Medicine) which showed that children from disadvantaged socioeconomic backgrounds were most likely to meet criteria for ADHD, yet least likely to receive consistent ADHD pharmacotherapy. Interested in understanding why certain children (including those with low socioeconomic status) may be more vulnerable to ADHD than others, she also studies the contribution of environmental exposures to ADHD and their public health impact. In Pediatrics, she published the first study to investigate the interactive effects of prenatal tobacco exposure and childhood lead exposure on ADHD and demonstrated that the association between poverty and ADHD is partially explained by the effects of these common environmental toxicants. She has also examined possible gene-environment interactions and found that boys with specific dopamine-related genetic variants were particularly susceptible to the adverse effects of lead exposure on ADHD-related executive functioning (published in Biological Psychiatry). Dr. Froehlich continues to research environmental influences on ADHD as a co-investigator on a National Institute of Environmental Health Sciences R01 grant which is examining the effects of pyrethroid pesticide exposure on ADHD symptoms and executive functioning.     

Dr. Froehlich’s research agenda also addresses ADHD treatment. She is the recipient of a National Institute of Mental Health K23 Award aimed at identifying genetic and phenotypic predictors of ADHD medication response.  Recently, she authored a paper in the Journal of the American Academy of Child and Adolescent Psychiatry showing that individuals with the dopamine receptor D4 and dopamine transporter genotypes believed to confer lower susceptibility to ADHD had greater improvement in their hyperactive-impulsive symptoms with methylphenidate treatment than those with the “high risk” genetic variants. She also coauthored a study on a novel genotyping assay for carboxylesterase 1 (CES1), the enzyme which metabolizes methylphenidate, and is currently undertaking a study on CES1 genetic variants’ effects on methylphenidate response. 

Dr. Froehlich also enhances care for children with ADHD through teaching and other professional activities. She has served as an invited speaker providing seminars for professionals and workshops for families in international, national, and regional forums. Currently, Dr. Froehlich co-chairs the Society for Developmental and Behavioral Pediatrics ADHD Special Interest Group, and coordinates ADHD-related projects and educational seminars for the Society membership in this capacity.

BA:  East Asian Studies, Columbia University, 1992.

MD: Yale University School of Medicine, 1999.

MS: Epidemiology, University of Cincinnati, 2007.

Pediatric Intern:  Children’s Hospital of Philadelphia, 1999-2000.

Pediatric Resident:  Children’s Hospital of Philadelphia, 2000-2002.

Fellowship: Developmental and Behavioral Pediatrics, Cincinnati Children’s Hospital, 2002-2005; General Pediatrics National Research Service Award Fellow, Cincinnati Children’s Hospital, 2004-2007.

Zhu HJ, Brinda B, Froehlich TE, Markowitz JS. A Discriminative Analytical Method for Detection of CES1A1 and CES1A2/CES1A3 Genetic Variants. Pharmacogenetics and Genomics. 2012; 22(3): 215-218.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS. Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry.  2011;11:1129-1139.

Froehlich TE, Anixt J, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman R. Update on Environmental Risk Factors for Attention-Deficit/Hyperactivity DisorderCurrent Psychiatry Reports. 2011;13(5):333-44.

Epstein JN, Brinkman WB, Froehlich T, Langberg JM, Narad ME, Antonini TN, Shiels K, Simon JO, Altaye M. Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD. Neuropsychopharmacology. 2011; 36(5): 1060-1072.

Langberg JM, Vaughn AJ, Brinkman WB, Froehlich T, Epstein, JN. Clinical utility of the Vanderbilt ADHD rating scale for identifying children without comorbid learning disorders. Pediatrics.  2010; 126: e1033-e1038.

Froehlich TE, McGough JJ, Stein MA. Progress and Promise of ADHD Pharmacogenetics. CNS Drugs. 2010; 24: 99-117.

Froehlich TE, Lanphear BP, Auinger P, Hornung R, Epstein JN, Braun J, Kahn RS.  The Association of Tobacco and Lead Exposure with Attention-Deficit/Hyperactivity Disorder in a National Sample of U.S. Children. Pediatrics. 2009; 124: e1054-63.

Langberg JM, Froehlich TE, Loren RE, Martin JE, Epstein JN. Assessing Children with ADHD in Primary Care Settings. Expert Rev Neurother. 2008; 8: 627-41.

Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence and Treatment of ADHD in a National Sample of U.S. ChildrenArchives of Pediatrics and Adolescent Medicine. 2007;161(9):  857-864.    

Froehlich TE, Lanphear BP, Dietrich KN, Cory-Slechta DA, Wang N, Kahn RS. Interactive Effects of a DRD4 Polymorphism, Lead, and Sex on Executive Functions in Children. Biological Psychiatry. 2007; 62:  243-249.

Medication Response in Children with Predominantly Inattentive Type ADHD.  Principal Investigator.  National Institute of Mental Health Career Development (K23).  2009-2014.